MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Drug-induced parkinsonism(DIP)"

  • 2023 International Congress

    Functional Neuroimaging and Follow up trends in Drug induced movement disorders.

    V. Mathur, A. Shetty, H. Shah, V. Lele, P. Wadia (Jaipur, India)

    Objective: To analyse the role of presynaptic dopaminergic imaging (TRODAT/ F Dopa PET) scans to predict long-term outcomes in patients of new onset parkinsonian symptoms…
  • 2022 International Congress

    Medication safety in Parkinson’s disease patients: evaluation of recommendations for decision support in the national drug-disease interaction database

    JJ. de Jong, CCM. Stuijt, MME. Diesveld, T. van Laar, SD. Borgsteede (Groningen, Netherlands)

    Objective: Objective: Drug-disease interactions in Parkinson's disease patients can give rise to situations where a drug may have negative effects on both motor- and non-motor…
  • 2022 International Congress

    Covid vaccine induced parkinsonism and cognitive dysfunction

    R. Dhamija, P. Talwar, S. Kushwaha, K. Gowdar (Delhi, India)

    Objective: To describe movement disorder and cognitive impairment in two patients following COVID-19 vaccination. Background: The manifestation of neurological complications have been increasingly evidenced following…
  • 2022 International Congress

    Beta-agonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies

    A. Singh, S. Hussain, B. Antony (Hobart, Australia)

    Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of beta-agonist and the risk of PD.…
  • 2022 International Congress

    Belly Dance Dyskinesia, a manifestation of B12 deficiency and hyperhomocysteinuria in MTHFR gene mutation. Videographic record of a case.

    D. López Domínguez, B. Solano Vila, A. Cots Foraster (Girona, Spain)

    Objective: We present a case of probable Belly Dance Dyskinesia (BDD) secondary to vitamin B12 deficiency. Background: BDD is a rare movement disorder (considered a…
  • 2022 International Congress

    To be or not to bupropion: a drug-induced parkinsonism?

    A. Silva, J. Pinto, M. Gago, M. Rodrigues (Braga, Portugal)

    Objective: To draw attention to drug-induced parkinsonism. Background: Although the main causes of parkinsonism are degenerative, there are some reversible causes, including drug-induced parkinsonism. Method:…
  • 2022 International Congress

    Levosulpiride and Movement Disorders–A Growing Concern

    D. Radhakrishnan, S. Gomathy, R. Rajan, A. Srivastava, A. Das, A. Agarwal, A. Pandit, V. Goyal (New Delhi, India)

    Objective: To describe a series of patients with levosulpiride (LVS) induced movement disorders (LIM) evaluated at a single movement disorder center, the All India Institute…
  • 2022 International Congress

    A STUDY OF CLINICAL SPECTRUM, RISK FACTORS AND OUTCOME OF DRUG-INDUCED MOVEMENT DISORDERS

    R. Anand, S. Pandey, HS. Malhotra, RK. Garg, N. Kumar, R. Uniyal, I. Rizvi (Lucknow, India)

    Objective: We aimed to characterize the spectrum of DIMDs, and the culprit agents commonly encountered in the movement disorder clinic. We also set out to…
  • 2022 International Congress

    Paliperidone induced neuroleptic malignant syndrome treated with electroconvulsive therapy and continuous apomorphine: A case report

    M. Gultekin, S. Benli (Kayseri, Turkey)

    Objective: Neuroleptic malignant syndrome (NMS) is a neurological emergency that is often induced by antipsychotic drugs. NMS may be mortal if left untreated. Background: In…
  • 2022 International Congress

    Novel Antipsychotics and Risk of Drug-Induced Movement Disorders and Tardive Syndromes

    G. Kannarkat, S. Caroff, J. Morley (Philadelphia, USA)

    Objective: To review evidence on the risk of drug-induced movement disorders (DIMDs) with newer antipsychotic (AP) drugs. Background: DIMDs, both acute/subacute “extrapyramidal symptoms” and chronic…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley